title: Laryngeal Kaposi's Sarcoma Complicated by the Immune Reconstitution Inflammatory Syndrome in an HIV-infected Patient.
abstract: We herein report a case of laryngeal Kaposi's sarcoma (KS) complicated by immune reconstitution inflammatory syndrome in a human immunodeficiency virus (HIV)-infected patient. The patient initially presented with KS involving the larynx, which was successfully treated with pegylated liposomal doxorubicin (PLD) and antiretroviral therapy (ART). PLD was discontinued after 2 courses because of a marked clinical improvement; however, the patient experienced progressive odynophagia and dyspnea 2 months after the initiation of ART. Laryngoscopy revealed a severely swollen, inflamed epiglottis. The readministration of PLD was successful, and the patient was thereafter discharged without any subsequent complications.
authors.affiliation: Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Japan.
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Kato
authors.forename: Naoki
authors.initials: N
authors.lastname: Yanagisawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Morioka
authors.forename: Shugo
authors.initials: S
authors.lastname: Sasaki
authors.forename: Noritaka
authors.initials: N
authors.lastname: Sekiya
authors.forename: Akihiko
authors.initials: A
authors.lastname: Suganuma
authors.forename: Akifumi
authors.initials: A
authors.lastname: Imamura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ajisawa
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000188:drug therapy / Q000209:etiology*; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000209:etiology*
chemical_list: D044966:Anti-Retroviral Agents; D000970:Antineoplastic Agents; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin